Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $61.00 | Peer Perform → Outperform | Wolfe Research |
| 3/18/2025 | $67.00 | Outperform | RBC Capital Mkts |
| 1/17/2025 | $62.00 → $82.00 | Neutral → Buy | Goldman |
| 11/5/2024 | $92.00 → $73.00 | Outperform | Wedbush |
| 8/26/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | $104.00 | Outperform | Oppenheimer |
| 4/2/2024 | $62.00 | Neutral | Goldman |
| 2/15/2024 | $77.00 | Outperform | Wolfe Research |
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
Wolfe Research upgraded MoonLake Immunotherapeutics from Peer Perform to Outperform and set a new price target of $61.00
RBC Capital Mkts initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $67.00
Goldman upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $82.00 from $62.00 previously